Bank of New York Mellon’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.33M | Buy |
106,792
+5,779
| +6% | +$234K | ﹤0.01% | 2350 |
|
|
2025
Q1 | $5.19M | Sell |
101,013
-915
| -0.9% | -$47K | ﹤0.01% | 2192 |
|
|
2024
Q4 | $5.64M | Buy |
101,928
+498
| +0.5% | +$27.6K | ﹤0.01% | 2219 |
|
|
2024
Q3 | $3.34M | Sell |
101,430
-21,204
| -17% | -$697K | ﹤0.01% | 2499 |
|
|
2024
Q2 | $3.33M | Buy |
122,634
+26,225
| +27% | +$713K | ﹤0.01% | 2534 |
|
|
2024
Q1 | $3.5M | Buy |
96,409
+14,212
| +17% | +$517K | ﹤0.01% | 2489 |
|
|
2023
Q4 | $1.66M | Buy |
82,197
+10,745
| +15% | +$218K | ﹤0.01% | 2920 |
|
|
2023
Q3 | $1.27M | Sell |
71,452
-179
| -0.2% | -$3.18K | ﹤0.01% | 3032 |
|
|
2023
Q2 | $1.29M | Buy |
71,631
+12,918
| +22% | +$233K | ﹤0.01% | 3058 |
|
|
2023
Q1 | $738K | Sell |
58,713
-538
| -0.9% | -$6.76K | ﹤0.01% | 3277 |
|
|
2022
Q4 | $869K | Buy |
59,251
+5,103
| +9% | +$74.8K | ﹤0.01% | 3260 |
|
|
2022
Q3 | $927K | Buy |
54,148
+9,566
| +21% | +$164K | ﹤0.01% | 3247 |
|
|
2022
Q2 | $651K | Buy |
44,582
+19,471
| +78% | +$284K | ﹤0.01% | 3436 |
|
|
2022
Q1 | $423K | Sell |
25,111
-175
| -0.7% | -$2.95K | ﹤0.01% | 3812 |
|
|
2021
Q4 | $569K | Buy |
25,286
+763
| +3% | +$17.2K | ﹤0.01% | 3721 |
|
|
2021
Q3 | $529K | Buy |
24,523
+2,950
| +14% | +$63.6K | ﹤0.01% | 3776 |
|
|
2021
Q2 | $625K | Buy |
21,573
+6,099
| +39% | +$177K | ﹤0.01% | 3662 |
|
|
2021
Q1 | $499K | Sell |
15,474
-2,943
| -16% | -$94.9K | ﹤0.01% | 3688 |
|
|
2020
Q4 | $761K | Buy |
+18,417
| New | +$761K | ﹤0.01% | 3407 |
|